Payment overview · 2025
General Payments
$203.60
5 reported records · 5 companies
Healthcare provider profile · identity verified
Emilio Ivan Perez, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BRONX, NY · NPI 1912149915
Verified facts
What the public records show
CMS Open Payments records show Emilio Ivan Perez, MD received $203.60 in general payments during 2025 across 5 reported records.
Madrigal Pharmaceuticals accounted for 63.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $130.14 | 63.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.54 | 10.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.72 | 9.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.69 | 8.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.51 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.60 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $130.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 245 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 887 | 286 |
| Metformin Hcl | Metformin Hcl | 427 | 138 |
| Omeprazole | Omeprazole | 404 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 99 |
| Gabapentin | Gabapentin | 285 | 99 |
| Glipizide | Glipizide | 257 | 61 |
| Jardiance | Empagliflozin | 245 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 234 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 63 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 210 | 46 |
| Meclizine Hcl | Meclizine Hcl | 182 | 65 |
| Lisinopril | Lisinopril | 178 | 54 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 157 | 26 |
| Losartan Potassium | Losartan Potassium | 154 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 39 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 132 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 132 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 22 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 122 | 47 |
| Meloxicam | Meloxicam | 122 | 65 |
| Trulicity | Dulaglutide | 120 | 22 |
| Famotidine | Famotidine | 118 | 49 |
| Simvastatin | Simvastatin | 117 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 112 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 107 | 31 |
| Montelukast Sodium | Montelukast Sodium | 102 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 30 |
| Carvedilol | Carvedilol | 86 | 22 |
| Celecoxib | Celecoxib | 86 | 53 |
| Ezetimibe | Ezetimibe | 82 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 67 |
| Ibuprofen | Ibuprofen | 79 | 32 |
| Ozempic | Semaglutide | 78 | 17 |
| Alendronate Sodium | Alendronate Sodium | 75 | 21 |
| Mirtazapine | Mirtazapine | 75 | 28 |
| Donepezil Hcl | Donepezil Hcl | 71 | 24 |
| Furosemide | Furosemide | 69 | 33 |
| Promethazine Hcl | Promethazine Hcl | 67 | 50 |
| Chlorthalidone | Chlorthalidone | 63 | 17 |
| Tramadol Hcl | Tramadol Hcl | 63 | 23 |
| Trazodone Hcl | Trazodone Hcl | 63 | 29 |
| Azithromycin | Azithromycin | 58 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 29 |
| Labetalol Hcl | Labetalol Hcl | 53 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 15 |
| Eliquis | Apixaban | 49 | 12 |
| Dexamethasone | Dexamethasone | 48 | 37 |
| Nifedipine Er | Nifedipine | 48 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 33 |
| Januvia | Sitagliptin Phosphate | 47 | 16 |
| Linzess | Linaclotide | 46 | suppressed |
| Novolog Flexpen | Insulin Aspart | 45 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 13 |
| Single Use Swab | Alcohol Antiseptic Pads | 44 | 17 |
| Etodolac | Etodolac | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Alcohol Wipes | Alcohol Antiseptic Pads | 41 | 12 |
| Metformin Hcl Er | Metformin Hcl | 40 | 16 |
| Azelastine Hcl | Azelastine Hcl | 39 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 38 | 20 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 15 |
| Clonidine | Clonidine | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 13 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | 12 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 15 |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | 15 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 21 | 16 |
| Alcohol Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Naproxen | Naproxen | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | 11 |
| Lactulose | Lactulose | 18 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.60 · 5 records | Madrigal Pharmaceuticals | AREXVY, JARDIANCE, Kerendia, REZDIFFRA, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error